In recent years the management of non-muscle-invasive bladder cancer has undergone radical changes. Intravesical Bacillus Calmette-Guérin (BCG) has long been established as the therapeutic standard ...
A review of studies including 20,000 patients with NMIBC highlights the need for individualized NMIBC management that balances oncologic control with QoL and patient-reported outcomes. Frequent ...
PARSIPPANY, N.J.--(BUSINESS WIRE)--Ferring Pharmaceuticals today announced the first patient in the United States with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder ...
Long-term results of a phase 2 study of neoadjuvant chemotherapy combined with tislelizumab followed by radiotherapy for bladder-preserving treatment in selected high-risk/locally advanced muscle ...
ImmunityBio’s sBLA targets BCG-unresponsive papillary NMIBC without CIS, complementing the existing U.S. approval for CIS ...
A multicenter, open-label phase 1/2 study of TYRA-300 in advanced urothelial carcinoma and other solid tumors with activating FGFR3 alterations (SURF301). Background: Response rates (55-65%) with ...
After matching, standardized mean differences were <0.1 for all key covariates. NAI + BCG showed improved outcomes versus other bladder sparing therapies in the d-uo cohort, including increased ...
ImmunityBio Inc. IBRX shares are up Tuesday following the announcement that the National Comprehensive Cancer Network (NCCN) ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window "Medical ...
CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced treatment with ANKTIVA® (nogapendekin alfa inbakicept-pmln) plus Bacillus ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results